Researchers from five Catalan research centres have collaborated on a large-scale genetic study in search of new biomarkers and therapeutic targets that could reduce cardiovascular risk by modulating blood metabolites.
Researchers identify 6 genetic regions that could reduce cardiovascular risk Read More »
Maria Molina, scientific director of IDIBELL, moderated the round table on the research career at the ICS.
IDIBELL researchers have led the discovery of biomarkers that could improve the non-invasive detection of clinically relevant prostate cancer cases.
The results of the SIRAKI02 study show that the use of a new extracorporeal blood purification membrane reduces acute kidney failure after complex cardiac surgery.
Two studies reveal new therapeutic approaches for lung cancer patients with BRAFV600E and KRASG12C mutations. The advanced preclinical models generated by IDIBELL and ICO professionals have been essential for this research.
This new study, based on 1,886 women with sleep apnea, reveals a heterogeneous presentation of the pathology in women similar to that of men, contrary to previous literature that often associated women with a predominantly atypical presentation.
UMBRELLA addresses the stroke care process from diagnosis, prevention, episode care and rehabilitation.
IDIBELL participates in the European project UMBRELLA Read More »
The Stanford University Top 2% of Scientists, which includes the most impactful scientists of the world, includes this year 34 IDIBELL researchers, of which three reaffirm their position among the top 10 in Spain and four have first entered.
The Northwestern University (Chicago), IDIBELL and IBEC were awarded a NIH project that will help develop new treatments for spinal cord injuries and other neurodegenerative pathologies.
Pablo Naval, Laura Costas, Josep M. Aran and Antonella Consiglio will develop their research and innovation projects within the framework of this call.
Four IDIBELL researchers receive funding from the CaixaImpulse 2024 call Read More »
